| 000 | 01563 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513191514.0 | ||
| 264 | 0 | _c19990907 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/S0140-6736(05)70735-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAoki, E | |
| 245 | 0 | 0 |
_aPatients' concerns about clinical trials in Japan. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cMar 1999 |
||
| 300 |
_a1019-20 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aControl Groups |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisclosure |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 | _aEthical Review |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInformed Consent |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 |
_aTegafur _xtherapeutic use |
| 650 | 0 | 4 | _aTherapeutic Human Experimentation |
| 773 | 0 |
_tLancet (London, England) _gvol. 353 _gno. 9157 _gp. 1019-20 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(05)70735-2 _zAvailable from publisher's website |
| 999 |
_c10417552 _d10417552 |
||